News & Commentary

09.08.21 | Firms News

Dr. Craig Gordon Launches Alternative Investment Firm GordonMD Global Investments

Today Craig Gordon, MD, a licensed physician with over a decade of buy-side experience managing global biopharmaceutical portfolios, proudly announces the launch of GordonMD Global Investments.

09.08.21

Dr. Craig Gordon Launches Alternative Investment Firm GordonMD Global Investments

Today Craig Gordon, MD, a licensed physician with over a decade of buy-side experience managing global biopharmaceutical portfolios, proudly announces the launch of GordonMD Global Investments.

05.13.24

Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock

Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock

02.28.24

Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) (“Crinetics” or the “Company”), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today that it has agreed to sell 8,333,334 shares of its common stock at a price of $42.00 per share to a select group of institutional and accredited healthcare specialist investors in an oversubscribed private placement.

02.08.24

Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering

Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering

01.05.24

GordonMD® Announces Second Investment in Radiopharmaceutical Biotech Radionetics Oncology

GordonMD® Global Investments LP, a key investor in groundbreaking healthcare solutions, announced another strategic investment in Radionetics Oncology.

10.17.23

GordonMD® Announces Investment in Radiopharmaceutical Biotech Radionetics Oncology

Craig Gordon, MD, Chief Executive Officer of GordonMD® Global Investments LP, announced today that his firm has jointly invested in a private placement financing for Radionetics Oncology.

08.14.23

Taysha Gene Therapies Announces $150 Million Private Placement Financing

Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), announced today that it has entered into a securities purchase agreement for a private placement financing (the “PIPE”) that is expected to result in gross proceeds of approximately $150 million, before deducting placement agent commissions and offering expenses.

08.03.23

Kyverna Therapeutics Extends Series B Financing Round to $145 Million and Brings in New Investors

Kyverna Therapeutics (“Kyverna”), a clinical-stage cell therapy company with the mission of engineering a new class of therapies for autoimmune diseases, today announced the close of an oversubscribed $60 million Series B financing round extension, bringing the total Series B financing round to $145 million.

03.22.23

Flare Therapeutics Announces Oversubscribed $123 Million Series B Financing

Flare Therapeutics Inc. today announced a $123 million Series B financing co-led by GordonMD® Global Investments LP and Pfizer Ventures.

09.12.22

Spotlight Therapeutics Appoints Nallakkan Arvindan, Ph.D., MBA, as EVP and Chief Technology Officer

Dr. Arvindan Brings Two Decades of Broad Industry Expertise in Technology Development and Operations

07.12.22

Spotlight Therapeutics Appoints Visionary Global Pharma Drug Developer Antoine Yver, M.D., M.Sc. as First Independent Board Member

Dr. Yver Brings More Than 30 Years of Industry Experience Including 11 Different Biologics and Small Molecule New Drug Approvals

03.22.22

Spotlight Therapeutics Raises $36.5 Million Series B to Advance a Pipeline of Cell-Targeted In Vivo CRISPR Gene Editing Biologics

Spotlight Therapeutics, Inc. (“Spotlight”), a biotechnology company applying new insights to develop cell-targeted in vivo CRISPR gene editing biologics, today announced a $36.5M Series B financing to fuel a drive toward the clinic.

01.05.22

SalioGen Therapeutics Closes $115 Million Oversubscribed Series B Financing to Advance Gene CodingTM – A New Category of Genetic Medicine

SalioGen Therapeutics, a privately held biotechnology company developing Gene CodingTM, a new category of genetic medicine, today announced the completion of an oversubscribed and up-sized $115 million Series B financing.

11.03.21

Antios Therapeutics Raises $75 Million in a Series B-1 Funding to Advance Clinical Programs for HBV

We are excited to announce the completion of our Series B-1 financing, a $75 million raise co-led by GordonMD Global Investments and the EPIQ Capital Group.

09.07.22

The End of an Era – A Guide for Rational Capital Allocation in the New Private Biopharmaceutical Market

Up. That is the only direction the private biopharmaceutical market has known in the 5 years from 2017 to 2021 with total investments in private biopharmaceutical companies more than doubling from $12.3B in 2017 to $28.5B in 2021.

06.24.22

Headwinds And Opportunities in Biopharma

Although the biopharmaceutical sector is facing major headwinds due to a tough regulatory and political environment, COVID, inflation, rising interest rates, geopolitical stability, overcapitalized innovation, poor managerial execution, and more